homogenising solution provided by quantigene sample processing kit (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
homogenising solution provided by quantigene sample processing kit
Homogenising Solution Provided By Quantigene Sample Processing Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantigene+sample+processing+kit/homogenising+solution+provided+by+quantigene+sample+processing+kit/pm40613328-80-14-22
Average 90 stars, based on 1 article reviews
Homogenising Solution Provided By Quantigene Sample Processing Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantigene+sample+processing+kit/homogenising+solution+provided+by+quantigene+sample+processing+kit/pm40613328-80-14-22
Average 90 stars, based on 1 article reviews
homogenising solution provided by quantigene sample processing kit - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Formalin-fixed Paraffin-Embedded:Article Title: Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. Article Snippet: .. Quantigene sample Gene Expression:Article Title: Deconvolution of Cytochrome P450 Induction Mechanisms in HepaRG Nuclear Hormone Receptor Knockout Cells. Article Snippet: Omeprazole and flumazenil were purchased from Cayman Chemicals (Ann Arbor, MI). .. Williams’ E medium, Sterility:Article Title: Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models Article Snippet: .. Tissue punches were removed from RNA later and lysed with sterile beads in 300 μL/sample of homogenizing solution ( Expressing:Article Title: Activating PKC-ε induces HIV expression with improved tolerability Article Snippet: .. EGR1 and CD69 mRNA expression levels were measured in whole blood, processed using Affymetrix other:Article Title: SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma Article Snippet: One specific probe targeting the SLC14A1 transcript was designed for QuantiGeneTM Sample Processing Kit, |
![( A ) Chemical structures of C6 and C16. ( B ) Crystal structures of C6 or C16 bound to the WIN site of WDR5 with electrostatic surfaces mapped (PDB IDs: 6E23 ; 6UCS ). The image shows a close-up view of the WIN site. ( C ) Superimposed WIN site-binding conformations of C6 (green) and C16 (blue). ( D ) Transcript levels as determined by <t>QuantiGene</t> analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells (n = 2–3; mean ± SEM). Vertical dashed line indicates either 2 µM C6 (left) or 100 nM C16 (right). ( E ) Number of genes with significantly (false discovery rate [FDR] < 0.05) altered transcript levels following treatment of MV4;11 cells with C6 (2 µM) or C16 (100 nM) for 48 hr, as determined by RNA-Seq (n = 3). See for complete output of RNA-seq analysis. ( F ) Comparison of gene expression changes elicited by C6 (x-axis) and C16 (y-axis), represented as Log2 fold change (FC) compared to DMSO. WDR5-bound genes are colored red. Locations of RPL22L1 and ZMAT3 are indicated. ( G ) Overlap of genes with decreased (left) or increased (right) transcript levels in MV4;11 cells treated with C6 or C16. ( H ) Gene set enrichment analysis (GSEA) showing the distribution of genes suppressed in MV4;11 cells in response to C6 (left) or C16 (right) against the list of all genes bound by WDR5 in those cells . NES, normalized enrichment score. ( I ) Enrichment analysis of genes suppressed (left) or induced (right) by C6 or C16 in MV4;11 cells. KEGG and Hallmark.MSigDB pathways are shown. Fold enrichment of indicated pathways is presented on the x-axis, the number of genes is shown in italics in each bar, and colors represent -Log10 FDR. See for additional GSEA (Hallmark) and over-representation analysis (ORA) (Hallmark) analyses of differentially expressed genes. ( J ) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C6 (top) or C16 (bottom). Figure 1—source data 1. Output of RNA-seq analysis of MV4;11 cells treated with C6/C16. Figure 1—source data 2. GSEA Hallmark and over-representation analysis (ORA) Hallmark enrichment analysis of differentially expressed genes in RNA-seq.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7873/pmc11057873/pmc11057873__elife-90683-fig1.jpg)
![( A ) Crystal structures of C6 or C16 bound to the WIN Site of WDR5 with electrostatic surfaces mapped (PDB IDs: 6E23 ; 6UCS ). ( B ) Viabilities of MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) for 72 hr, relative to viability of DMSO-treated cells (n = 3; mean ± SEM). ( C ) As in ( B ) but for MOLM13 cells. ( D ) Transcript levels as determined by QuantiGene analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MOLM13 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells (n = 3; mean ± SEM). Vertical dashed line indicates either 2 µM C6 (left) or 100 nM C16 (right). ( E ) Transformed z-scores of genes with significantly altered transcript levels (RNA-seq) in MV4;11 cells treated with either C6 (2 µM) or C16 (100 nM) for 48 hr, compared to DMSO treatment. ( F ) Volcano plots, showing transcript level alterations in MV4;11 cells treated 48 hr with 2 µM C6 (left) or 100 nM C16 (right) compared to DMSO (n = 3; red indicates false discovery rate [FDR] < 0.05). ( G ) Dispersion plot describing the variance in gene expression for the RNA-seq data in a previous study (left) and this study (right).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7873/pmc11057873/pmc11057873__elife-90683-fig1-figsupp1.jpg)
